DC subsets (i.e., cDC1 and cDC2) have distinct phenotypes and functions that can differentially affect anti-tumor immune responses (Figure 4A) (cDC1: CD8+ T cell activation and CD4+ T cell licensing; cDC2: CD4+ T cell priming). Here, CD4 is linked to neoplasm.